Teva Pharmaceutical Industries Limited announced changes to its leadership team. Brendan O’Grady, Executive Vice President, North America Commercial, will leave the company to pursue a career opportunity outside of the pharmaceutical industry, and Sven Dethlefs, who currently serves as the company's Executive Vice President, Global Marketing and Portfolio and International Markets Commercial has been appointed the new head of North America Commercial. In addition, Teva announced the following changes to the Executive Management team: Mark Sabag, who currently serves as Chief Human Resources Officer and head of Global Communications, Brand and ESG, has been appointed as Executive Vice President, International Markets Commercial; Galia Inbar will be promoted to Executive Vice President, Chief Human Resources Officer, and Global Communications, Brand and ESG; Eli Shani will be promoted to Executive Vice President, Global Marketing and Portfolio. All changes will be effective August 15, 2021. Sven Dethlefs, PhD has been part of the Executive Management team since 2017 and has held numerous leadership roles of increasing responsibility in the company's global specialty business, commercial European business, and in global operations. Sven has played an integral role in optimizing Teva's vast global portfolio, in the R&D pipeline strategy, and leading global marketing teams including responsibility for AJOVY®, AUSTEDO® and Digital Health. Previously, he held positions as global head of respiratory medicines and chief operating officer of global manufacturing operations group, Teva Global Operations (TGO). Sven became Executive Vice President, Global Marketing & Portfolio in 2017 and assumed responsibility for international markets commercial in 2021. Sven joined Teva as general manager, Germany, in 2008. Prior to joining Teva, he served for over eleven years as a partner at McKinsey & Company. Sven received his Ph.D. in biochemistry from the FU Berlin/Pasteur Institute Paris.